These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 23832433)
1. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Sanmukhani J; Satodia V; Trivedi J; Patel T; Tiwari D; Panchal B; Goel A; Tripathi CB Phytother Res; 2014 Apr; 28(4):579-85. PubMed ID: 23832433 [TBL] [Abstract][Full Text] [Related]
2. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123 [TBL] [Abstract][Full Text] [Related]
3. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder. Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial. Yu YM; Gao KR; Yu H; Shen YF; Li HF J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692 [TBL] [Abstract][Full Text] [Related]
5. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related]
6. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
7. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. Lin CH; Lin SH; Jang FL J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699 [TBL] [Abstract][Full Text] [Related]
8. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study. Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213 [TBL] [Abstract][Full Text] [Related]
9. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722 [TBL] [Abstract][Full Text] [Related]
10. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Blier P; Ward HE; Tremblay P; Laberge L; Hébert C; Bergeron R Am J Psychiatry; 2010 Mar; 167(3):281-8. PubMed ID: 20008946 [TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Schatzberg A; Roose S Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045 [TBL] [Abstract][Full Text] [Related]
12. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339 [TBL] [Abstract][Full Text] [Related]
13. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533 [TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine. Ghosh R; Gupta R; Bhatia MS; Tripathi AK; Gupta LK Asian J Psychiatr; 2015 Dec; 18():37-41. PubMed ID: 26514447 [TBL] [Abstract][Full Text] [Related]
15. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Bergman J; Miodownik C; Bersudsky Y; Sokolik S; Lerner PP; Kreinin A; Polakiewicz J; Lerner V Clin Neuropharmacol; 2013; 36(3):73-7. PubMed ID: 23673908 [TBL] [Abstract][Full Text] [Related]
16. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans. Wong ML; Dong C; Flores DL; Ehrhart-Bornstein M; Bornstein S; Arcos-Burgos M; Licinio J Am J Psychiatry; 2014 Dec; 171(12):1297-309. PubMed ID: 25220861 [TBL] [Abstract][Full Text] [Related]
18. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026 [TBL] [Abstract][Full Text] [Related]
19. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. McIntyre RS; Fayyad R; Mackell JA; Boucher M Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542 [TBL] [Abstract][Full Text] [Related]
20. The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. Abdallah MS; Mosalam EM; Zidan AA; Elattar KS; Zaki SA; Ramadan AN; Ebeid AM Neurotherapeutics; 2020 Oct; 17(4):1897-1906. PubMed ID: 32500486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]